Kingdom
Assessment of the Pharmaceutical Sector: The Process Is Not Yet Completed
The Moroccan Agency for Medicines and Health Products provides clarifications regarding the assessment process of the national regulatory system for medicines and vaccines using the WHO GBT tool.
Following information circulated by certain electronic media regarding allegations of a supposed assessment or classification of the maturity level of the Kingdom of Morocco’s national regulatory system for medicines and vaccines, according to the World Health Organization’s (WHO) Global Benchmarking Tool (GBT), the Moroccan Agency for Medicines and Health Products (AMMPS) provides the following clarifications:
An Unfinalized Assessment: No Official Results at This Stage
The process of assessing the maturity level of the national regulatory system for medicines and vaccines, in accordance with the WHO’s GBT tool, is still ongoing and has not yet been finalized. Consequently, any reference to definitive results or an official classification remains premature and is not based on any official decision or publication from the WHO.
No Validated Final Report, No Level Attributed
To date, no final report has been issued or validated that attributes Maturity Level 3 (ML3) or any other level to Morocco. The information disseminated on this subject is not based on any reliable institutional data and does not reflect the actual status of the assessment process as recognized at the international level.
The GBT Framework, a Structured Technical Process
The GBT tool constitutes a rigorous technical and methodological framework, based on progressive stages including self-assessment, documentary analysis, technical consultations, and field missions conducted by international experts, prior to any official conclusion. The results of this process cannot be anticipated or confirmed until the completion of all stages and their exclusive final validation by the WHO.
Improvement in the Performance of the National Regulatory System
Within this framework, the WHO experts and inspectors accompanying the AMMPS conducted a field mission from December 8 to 12, 2025. This mission observed tangible and significant improvements in the performance of the national regulatory system, based on the objective and documented evidence presented, as well as progress made in several essential regulatory functions, as part of an ongoing dynamic of reform and institutional strengthening.
The AMMPS regrets the circulation, in certain media, of information and evaluations presented as results, when they are not based on any authorized official source and have not been the subject of any institutional coordination with the competent authorities. Such allegations are likely to mislead public opinion and undermine the technical and institutional efforts deployed.
While reaffirming its total and responsible commitment to this process, the AMMPS reiterates its dedication to continuing the strengthening of the national regulatory system for medicines and health products in accordance with the best international standards and practices; a close, transparent, and structured partnership with the World Health Organization; and rigorous and responsible institutional communication, based exclusively on official and duly validated data.
Upon the completion of the assessment process and its final validation by the World Health Organization, the Moroccan Agency for Medicines and Health Products will officially communicate the results through its authorized institutional channels, respecting the principles of transparency, credibility, and service to the public interest.
